Breaking News Instant updates and real-time market news.

2022-05-24 12:14:29 ACSAY ACS $5.43 / +0.09 (+1.69%) 12:14 05/24/22 05/24 12:14 05/24/22 12:14	ACS downgraded to Neutral from Buy at Goldman Sachs Goldman Sachs analyst Patrick Creuset downgraded ACS to Neutral from Buy with an unchanged price target of EUR 29. While he raised his 2022-27 EBIT forecasts by 2% on average following what he calls "a solid set" of Q1 results, his 2023/24 EBIT estimates remain about 10% below Visible Alpha consensus and he sees more potential upside in other names he covers, Creuset tells investors.

2022-05-24 12:14:29

ACSAY

ACS

$5.43 / +0.09 (+1.69%)

12:14

05/24/22

05/24

12:14

05/24/22

12:14

ACS downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs analyst Patrick Creuset downgraded ACS to Neutral from Buy with an unchanged price target of EUR 29. While he raised his 2022-27 EBIT forecasts by 2% on average following what he calls "a solid set" of Q1 results, his 2023/24 EBIT estimates remain about 10% below Visible Alpha consensus and he sees more potential upside in other names he covers, Creuset tells investors.

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Altimmune price target raised to $26 from $21 at B. Riley » 08:19 08/12/22 08/12 08:19 08/12/22 08:19 ALT Altimmune $13.75 / +0.87 (+6.75%) B. Riley analyst Mayank… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly ALT Altimmune $13.75 / +0.87 (+6.75%) 04/01/22 Altimmune initiates 48-week Phase 2 MOMENTUM trial of pemvidutide ALT Altimmune $13.75 / +0.87 (+6.75%) 08/11/22 Piper Sandler Piper has 'strong conviction on pemvidutide,' still bullish on Altimmune 08/03/22 Piper Sandler Piper says Altimmune selloff related to Novo continuing Phase 3 SELECT trial 05/17/22 Piper Sandler Altimmune price target lowered to $25 from $34 at Piper Sandler 04/28/22 Piper Sandler Lilly data does not raise bar for Altimmune, says Piper Sandler ALT Altimmune $13.75 / +0.87 (+6.75%) 08/11/22 Altimmune reports Q2 EPS (42c) vs (60c) last year 05/12/22 Altimmune reports Q1 EPS (44c), consensus (58c) 03/15/22 Altimmune reports Q4 EPS (57c), consensus (65c) ALT Altimmune $13.75 / +0.87 (+6.75%) 03/15/22 Fly Intel: Pre-market Movers
Recommendations	Petco price target lowered to $22 from $27 at Wells Fargo » 08:17 08/12/22 08/12 08:17 08/12/22 08:17 WOOF Petco $15.55 / +0.255 (+1.67%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options WOOF Petco $15.55 / +0.255 (+1.67%) 08/09/22 Petco announces leadership team appointments 06/16/22 Petco launches new pet care retail centers for small-town and rural markets 05/24/22 Petco jumps 5% to $15.35 after Q1 results top estimates 05/09/22 PetMed Express appoints Carden as VP of Product Management WOOF Petco $15.55 / +0.255 (+1.67%) 07/26/22 Wedbush Wedbush removes Petco from Best Ideas List, lowers price target to $18 from $25 06/27/22 Goldman Sachs Petco price target lowered to $21 from $23 at Goldman Sachs 06/21/22 Guggenheim Petco assumed with a Neutral at Guggenheim 05/25/22 Citi Petco price target lowered to $20 from $26 at Citi WOOF Petco $15.55 / +0.255 (+1.67%) 05/24/22 Petco backs FY22 adjusted EPS 97c-$1.00, consensus 99c 05/24/22 Petco reports Q1 adjusted EPS 17c, consensus 15c 05/23/22 Notable companies reporting before tomorrow's open 05/23/22 Notable companies reporting before tomorrow's open WOOF Petco $15.55 / +0.255 (+1.67%) 06/04/22 Short Report: GameStop short position reaches 15-month high 05/24/22 What You Missed On Wall Street On Tuesday 05/24/22 What You Missed On Wall Street This Morning 05/24/22 Fly Intel: Pre-market Movers 08/24/22 Petco - WOOF WOOF Petco $15.55 / +0.255 (+1.67%) 05/23/22 Petco put volume heavy and directionally bearish 03/22/22 Largest borrow rate increases among liquid names
Periodicals	Five China-owned companies to delist from US exchanges, Bloomberg reports » 08:17 08/12/22 08/12 08:17 08/12/22 08:17 LFC China Life Insurance $7.51 / +0.175 (+2.39%) , PTR PetroChina $44.91 / +0.78 (+1.77%) , SNP Sinopec $47.17 / +0.35 (+0.75%) , ACH Aluminum Corp. of China $9.17 / -0.005 (-0.05%) , SHI Sinopec Shanghai $16.07 / +0.11 (+0.69%) Five of China's… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings PTR SNP ACH PTR PetroChina $44.91 / +0.78 (+1.77%) 06:04 Today PetroChina to delist shares from NYSE SNP Sinopec $47.17 / +0.35 (+0.75%) 06:05 Today Sinopec to delist shares from NYSE ACH Aluminum Corp. of China $9.17 / -0.005 (-0.05%) 04/25/22 Aluminum Corp. of China falls -13.3% 04/25/22 Aluminum Corp. of China falls -9.7% 04/13/22 Aluminum Corp. of China rises 5.7% 03/08/22 Aluminum Corp. of China falls -9.2% LFC PTR SNP ACH SHI LFC China Life Insurance $7.51 / +0.175 (+2.39%) 08/05/22 JPMorgan China Life Insurance upgraded to Overweight from Neutral at JPMorgan PTR PetroChina $44.91 / +0.78 (+1.77%) 05/23/22 Citi PetroChina upgraded to Neutral from Sell at Citi 01/04/22 Citi PetroChina downgraded to Sell from Neutral at Citi 11/29/21 JPMorgan PetroChina upgraded to Overweight from Underweight at JPMorgan 10/13/21 JPMorgan PetroChina downgraded to Underweight from Overweight at JPMorgan SNP Sinopec $47.17 / +0.35 (+0.75%) 06/19/22 Goldman Sachs Sinopec downgraded to Sell from Neutral at Goldman Sachs 05/23/22 Citi Sinopec downgraded to Sell from Buy at Citi ACH Aluminum Corp. of China $9.17 / -0.005 (-0.05%) 03/23/22 HSBC Aluminum Corp. of China upgraded to Hold from Reduce at HSBC 01/13/22 Goldman Sachs Aluminum Corp. of China downgraded to Sell from Buy at Goldman Sachs SHI Sinopec Shanghai $16.07 / +0.11 (+0.69%) 06/28/22 Morgan Stanley Sinopec Shanghai downgraded to Equal Weight from Overweight at Morgan Stanley 04/19/22 JPMorgan Sinopec Shanghai downgraded to Underweight from Neutral at JPMorgan 09/27/21 JPMorgan Sinopec Shanghai initiated with a Neutral at JPMorgan PTR PTR PetroChina $44.91 / +0.78 (+1.77%) 03/31/22 PetroChina reports 2021 revenue RMB 2.6T, up 35.2% vs. last year
Recommendations	SmartRent price target lowered to $5.25 from $6.00 at Cantor Fitzgerald » 08:15 08/12/22 08/12 08:15 08/12/22 08:15 SMRT SmartRent $5.56 / +0.015 (+0.27%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SMRT SmartRent $5.56 / +0.015 (+0.27%) 08/11/22 SmartRent falls 28% to $4.02 after Q2 earnings miss and guidance cut 05/17/22 SmartRent director buys $1.04M in common stock 04/28/22 SmartRent names Hiroshi Okamoto CFO 03/24/22 SmartRent acquires SightPlan for about $135M in all-cash transaction SMRT SmartRent $5.56 / +0.015 (+0.27%) 07/22/22 Cantor Fitzgerald SmartRent assumed with an Overweight at Cantor Fitzgerald 07/19/22 Keefe Bruyette Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette 05/25/22 Compass Point Compass Point starts SmartRent at Buy, sees 'exponential growth potential' 05/25/22 Compass Point SmartRent initiated with a Buy at Compass Point SMRT SmartRent $5.56 / +0.015 (+0.27%) 08/11/22 SmartRent cuts FY22 revenue view to $155M-$180M from $220M-$250M 08/11/22 SmartRent sees Q3 revenue $43M-$47M, consensus $75.4M 08/11/22 SmartRent reports Q2 EPS (13c), consensus (11c) 05/11/22 SmartRent sees FY22 revenue $220M-$250M, consensus $238.1M SMRT SmartRent $5.56 / +0.015 (+0.27%) 08/11/22 Fly Intel: After-Hours Movers 05/11/22 Fly Intel: After-Hours Movers 03/24/22 Fly Intel: After-Hours Movers 02/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Upgrade	Deutsche Bank raises Sanofi to Hold, calls Zantac 'knee-jerk' reaction overdone » 08:15 08/12/22 08/12 08:15 08/12/22 08:15 SNY Sanofi $43.46 / -1.74 (-3.85%) As previously reported,… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 Sanofi says 'confident in its legal defenses' related to U.S. Zantac litigation 08/04/22 Sanofi announces strategic collaboration with Innovent Biologics 07/21/22 Innate Pharma announces Sanofi decision to progress IPH6401/SAR'514 07/18/22 Editas Medicine appoints Mei as SVP, CMO SNY Sanofi $43.46 / -1.74 (-3.85%) 07:40 Today JPMorgan Sanofi may not be liable for any Zantac litigation damages, says JPMorgan 05:33 Today Deutsche Bank Sanofi upgraded to Hold from Sell at Deutsche Bank 08/11/22 JPMorgan Perrigo, Pfizer appear to have manageable Zantac exposure, says JPMorgan 08/11/22 Deutsche Bank Zantac cases likely a short-term headwind for GSK, Sanofi, says Deutsche Bank SNY Sanofi $43.46 / -1.74 (-3.85%) 07/28/22 Sanofi sees 2022 business EPS growing 15% at CER 07/28/22 Sanofi reports Q2 business EPS EUR 1.73, up 16.7% at CER 04/28/22 Sanofi still expects 2022 business EPS to grow low double-digit at CER 04/28/22 Sanofi reports Q1 business EPS EUR 1.94, up 16.1% at CER SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 GSK, Sanofi weakness related to Zantac litigation worries, Bloomberg reports SNY Sanofi $43.46 / -1.74 (-3.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 Renewed Zantac litigation concerns sinking these big-cap drugmakers 08/11/22 What You Missed On Wall Street This Morning 06/24/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022
Earnings	Xenetic reports Q2 net loss $2.7M » 08:13 08/12/22 08/12 08:13 08/12/22 08:13 XBIO Xenetic / + The Company ended the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research XBIO Xenetic / + 08/02/22 Xenetic, VolitionRx collaborate to develop NETs-targeted adoptive cell therapies 07/07/22 Xenetic enters manufacturing agreement with Catalent Pharma Solutions 07/07/22 Xenetic enters clinical manufacturing agreement with Catalent XBIO Xenetic / + 05/02/22 H.C. Wainwright Xenetic price target lowered to $4 from $5 at H.C. Wainwright
Recommendations	Pear Therapeutics price target lowered to $5 from $11 at BTIG » 08:12 08/12/22 08/12 08:12 08/12/22 08:12 PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) BTIG analyst Marie… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reduced workforce on July 25 due to macro environment 08/10/22 Pear Therapeutics announces publication of insomnia analysis 08/08/22 Pear Therapeutics, SelectHealth announce reSET-O added as covered benefit 08/03/22 Pear, Cove Behavioral avail patients PDT reSET-O for opiod abuse treatment PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 07:48 Today Chardan Pear Therapeutics price target lowered to $9 from $13 at Chardan 06/24/22 BTIG Pear Therapeutics price target lowered to $11 from $12 at BTIG 05/24/22 Cowen Pear Therapeutics revenues raised on strong Rx growth, says Cowen 05/17/22 Chardan Pear Therapeutics price target lowered to $13 from $16 at Chardan PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Pear Therapeutics reports Q2 EPS 4c, consensus (25c) 05/16/22 Pear Therapeutics backs FY22 revenue view $22M, consensus $21.06M 05/16/22 Pear Therapeutics reports Q1 EPS (17c), consensus (24c) 03/28/22 Pear Therapeutics sees FY22 revenue $22M, consensus $21.79M PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 08/11/22 Fly Intel: After-Hours Movers 05/16/22 Fly Intel: After-Hours Movers PEAR Pear Therapeutics $2.25 / +0.27 (+13.64%) 05/11/22 Eighteen new option listings on May 11th
Recommendations	Plug Power price target raised to $29 from $19 at Wells Fargo » 08:12 08/12/22 08/12 08:12 08/12/22 08:12 PLUG Plug Power $27.74 / -1.04 (-3.61%) Wells Fargo analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/04/22 New Fortress Energy enters 120MW green hydrogen plant deal with Plug Power 08/04/22 Plug Power selected by New Fortress Energy for 120 MW green hydrogen plant 07/29/22 Microsoft posts blog detailing work with partner Plug Power 07/12/22 Plug Power secures 5MW electrolyzer sale to Irving Oil PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/11/22 Citi Plug Power price target raised to $36 from $20 at Citi 08/11/22 Truist Plug Power price target raised to $32 from $21 at Truist 08/10/22 B. Riley Plug Power price target raised to $32 from $31 at B. Riley 08/10/22 Cowen Plug Power price target lowered to $35 from $44 at Cowen PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/09/22 Plug Power reports Q2 EPS (30c) vs. (18c) last year 08/09/22 Notable companies reporting after market close 05/09/22 Plug Power reports Q1 EPS (27c), consensus (16c) 05/09/22 Notable companies reporting after market close PLUG Plug Power $27.74 / -1.04 (-3.61%) 08/09/22 Fly Intel: After-Hours Movers 08/08/22 What You Missed This Week in EVs and Clean Energy 06/13/22 What You Missed This Week in EVs and Clean Energy 06/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations PLUG Plug Power $27.74 / -1.04 (-3.61%) 07/28/22 Unusually active option classes on open July 28th 07/06/22 Plug Power call volume above normal and directionally bullish 06/27/22 Plug Power put volume heavy and directionally bearish 05/09/22 Unusually active option classes on open May 9th
Hot Stocks	Guardant Health receives FDA approval Guardant360 CDx liquid biopsy test as CDx » 08:11 08/12/22 08/12 08:11 08/12/22 08:11 GH Guardant Health $53.10 / +0.03 (+0.06%) , AZN AstraZeneca $64.66 / -1.175 (-1.78%) Guardant Health (GH)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/02/22 Guardant Health announces Medicare coverage for Guardant Reveal test 07/06/22 Guardant Health, Adicon Holdings announce CGP test partnership 06/13/22 Guardant Health completes purchase of AMEA joint venture 05/22/22 Guardant Health presents new data showing blood test accuracy in detecting CRC AZN AstraZeneca $64.66 / -1.175 (-1.78%) 06:23 Today AstraZeneca's Enherty approved in U.S. for NSCLC with ERBB2 mutations 08/11/22 AstraZeneca completes acquisition of TeneoTwo 08/09/22 Datopotamab deruxtecan combo shows 'promising clinical activity' in study 08/08/22 AstraZeneca, Hutchmed report results from SAVANNAH Phase II trial GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/03/22 Citi Exact Sciences price target lowered to $50 from $65 at Citi 08/02/22 Piper Sandler Guardant Health coverage news 'notable positive,' says Piper Sandler 08/01/22 OTR Global Guardant Health view downgraded to Mixed from Positive at OTR Global 06/02/22 Piper Sandler Guardant Health initiated with an Overweight at Piper Sandler AZN AstraZeneca $64.66 / -1.175 (-1.78%) 08/05/22 Morgan Stanley AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Morgan Stanley 08/04/22 Barclays AstraZeneca price target lowered to 12,000 GBp from 12,500 GBp at Barclays 08/01/22 JPMorgan AstraZeneca price target raised to 12,500 GBp from 12,000 GBp at JPMorgan 08/01/22 Deutsche Bank AstraZeneca price target raised to 12,000 GBp from 11,500 GBp at Deutsche Bank GH AZN GH Guardant Health $53.10 / +0.03 (+0.06%) 08/04/22 Guardant Health backs FY22 revenue $460M-$470M, consensus $465.29M 08/04/22 Guardant Health reports Q2 adjusted EPS ($1.00), consensus ($1.21) 05/05/22 Guardant Health backs FY22 revenue view $460M-$470M, consensus $465.93M 05/05/22 Guardant Health reports Q1 adjusted EPS (91c), consensus ($1.21) AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/29/22 AstraZeneca backs FY22 core EPS view up by mid to high twenties percentage 07/29/22 AstraZeneca reports Q2 core EPS $1.72, up 89% year-over-year 04/29/22 AstraZeneca backs FY22 core EPS up by mid to high twenties percentage 04/29/22 AstraZeneca reports Q1 core EPS $1.89, up 20% y/y AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports 05/10/22 Emergent plant's quality problems led to 400M discarded vaccines, WSJ reports 03/23/22 AstraZeneca preventive COVID shot set to win EU clearance, Reuters says AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/05/22 Fly Intel: Pre-market Movers 05/24/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/06/22 Fly Intel: Pre-market Movers 03/23/22 What You Missed On Wall Street On Wednesday 08/29/22 Med Tech & Life Sciences West Coast Field Trip 09/10/22 ESMO Congress 2022 AZN AZN AstraZeneca $64.66 / -1.175 (-1.78%) 07/20/22 AstraZeneca call volume above normal and directionally bullish 06/06/22 Unusually active option classes on open June 6th 04/26/22 AstraZeneca call volume above normal and directionally bullish 04/07/22 AstraZeneca put volume heavy and directionally bearish
Hot Stocks	Kalera announces revised date for Q2 financial results » 08:10 08/12/22 08/12 08:10 08/12/22 08:10 KAL Kalera $2.93 / +0.19 (+6.93%) Kalera Public Limited… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events KAL Kalera $2.93 / +0.19 (+6.93%) 06/30/22 Agrico Acquisition Corp trading resumes 06/30/22 Agrico Acquisition Corp trading halted, volatility trading pause 06/29/22 Kalera, Agrico Acquisition complete business combination KAL Kalera $2.93 / +0.19 (+6.93%) 07/07/22 Roth Capital Kalera initiated with a Buy at Roth Capital 08/15/22 Kalera - KAL

Hot Stocks	Rubicon sets record date for its $11 per share cash distribution » 08:09 08/12/22 08/12 08:09 08/12/22 08:09 RBCN Rubicon $16.10 / + (+0.00%) Rubicon Technology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News RBCN Rubicon $16.10 / + (+0.00%) 07/05/22 Janel to launch cash tender offer to acquire 45% interest in Rubicon 05/10/22 Rubicon announces launch of RUBICONSelect
Recommendations	Rivian Automotive price target raised to $27 from $24 at DA Davidson » 08:09 08/12/22 08/12 08:09 08/12/22 08:09 RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian Automotive cuts FY22 adjusted EBITDA target to loss of $5.45B from $4.75B 08/11/22 Rivian Auto says supply chain constraints 'to remain limiting factor' in output 08/11/22 Rivian Automotive reports Q2 output of 4.40K and deliveries of 4.47K vehicles 08/11/22 Rivian Automotive affirms 2022 production target of 25K vehicles RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 07:02 Today Morgan Stanley Rivian Automotive's liqudity can last through most of FY23, says Morgan Stanley 06:44 Today Mizuho Rivian Automotive price target lowered to $65 from $70 at Mizuho 07/18/22 Deutsche Bank Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank 07/13/22 Canaccord Rivian Automotive initiated with a Buy at Canaccord RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian Automotive reports Q2 EPS ($1.89), consensus ($1.67) 08/11/22 Notable companies reporting after market close 07/28/22 Amazon reports Q2 EPS (20c) with Rivian loss, consensus 13c 05/11/22 Rivian Automotive reports Q1 adjusted EPS ($1.43), consensus ($1.44) 10 Nov RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/02/22 Rivian says most vehicles ineligible under Senate climate deal, WSJ reports 07/27/22 Rivian cuts workforce by 6%, Bloomberg reports 07/27/22 Rivian cuts workforce by 6%, Bloomberg reports 07/12/22 Rivian plans all-hands meeting on Friday, CEO says in memo seen by Bloomberg RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Fly Intel: After-Hours Movers 08/03/22 Here's what Wall Street experts are saying about these EV names ahead of results 08/02/22 What You Missed On Wall Street On Tuesday 08/01/22 What You Missed This Week in EVs and Clean Energy RIVN Rivian Automotive $38.91 / +1.475 (+3.94%) 08/11/22 Rivian options imply 8.3% move in share price post-earnings 07/13/22 Rivian call volume above normal and directionally bullish 07/06/22 Unusually active option classes on open July 6th 06/21/22 Rivian call volume above normal and directionally bullish
Hot Stocks	GrowGeneration CFO Jeff Lasher resigns, Greg Sanders succeeds » 08:08 08/12/22 08/12 08:08 08/12/22 08:08 GRWG GrowGeneration $5.62 / -0.335 (-5.63%) GrowGeneration announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 06/27/22 GrowGeneration announces 2022 annual meeting results 02/15/22 GrowGeneration selects Manhattan Active Point of Sale for omnichannel sales GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 08/05/22 Alliance Global Partners GrowGeneration downgraded to Neutral from Buy at Alliance Global Partners 05/12/22 Oppenheimer GrowGeneration price target lowered to $15 from $50 at Oppenheimer 05/11/22 Wells Fargo GrowGeneration price target lowered to $4 from $8 at Wells Fargo 05/11/22 Alliance Global Partners GrowGeneration price target lowered to $7 from $14 at Alliance Global GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 08/04/22 GrowGeneration cuts FY22 revenue view to $250M-$275M from $340M-$400M 08/04/22 GrowGeneration reports Q2 adjusted EPS (6c), consensus (8c) 05/11/22 GrowGeneration cuts FY22 revenue view to $340M-$400M, consensus $426.5M 05/10/22 GrowGeneration reports Q1 EPS (9c), consensus (8c) GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 05/10/22 Fly Intel: After-Hours Movers 03/25/22 What You Missed On Wall Street On Friday 03/25/22 What You Missed On Wall Street This Morning GRWG GrowGeneration $5.62 / -0.335 (-5.63%) 07/25/22 Largest borrow rate increases among liquid names 05/16/22 Growgeneration call volume above normal and directionally bullish 04/14/22 Largest borrow rate increases among liquid names 04/05/22 Growgeneration call volume above normal and directionally bullish
Hot Stocks	XpresSpa announces re-opening of XpresSpa location at JFK Airport » 08:08 08/12/22 08/12 08:08 08/12/22 08:08 XSPA XpresSpa / + XpresSpa Group announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events Options XSPA XpresSpa / + 07/11/22 XpresSpa to open locations at Istanbul Airport in Turkey 06/14/22 XpresSpa names Haynes as interim CFO, Berry separation from company June 13 05/20/22 XpresSpa announces 10M share increase in stock repurchase 03/30/22 XpresSpa opens COVID-19 testing facility at Orlando International Airport XSPA XpresSpa / + 05/18/22 H.C. Wainwright XpresSpa price target lowered to $2 from $4 at H.C. Wainwright 03/16/22 H.C. Wainwright XpresSpa 'dislocation' brings buying opportunity, says H.C. Wainwright 11/17/21 H.C. Wainwright XpresSpa price target raised to $4 from $3.50 at H.C. Wainwright 08/15/22 XpresSpa - XSPA XSPA XpresSpa / + 04/12/22 Largest borrow rate increases among liquid names 04/08/22 Largest borrow rate increases among liquid names 03/28/22 Largest borrow rate increases among liquid names 03/15/22 XpresSpa options imply 18.0% move in share price post-earnings
Hot Stocks	Applied Blockchain secures $115M credit facility » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 APLD Applied Blockchain $2.15 / +0.04 (+1.90%) Applied Blockchain… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 08/01/22 Applied Blockchain appoints Regina Ingel as CMO 07/18/22 Applied, Marathon enter hosting contract for 200-MW Bitcoin mining capacity 06/13/22 Applied Blockchain announces expiration of share lock-up 06/08/22 Applied Blockchain announces 5% reduction in outstanding common shares APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/19/22 Lake Street Marathon contract gives Lake Street confidence in Applied Blockchain growth 05/23/22 Craig-Hallum Craig-Hallum bullish on Applied Blockchain, initiates with a Buy 05/23/22 Craig-Hallum Applied Blockchain initiated with a Buy at Craig-Hallum 05/09/22 Lake Street Applied Blockchain initiated with a Buy at Lake Street APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/18/22 Applied Blockchain narrows Q4 revenue view to $5.95M-$7.2M, consensus $5.68M 13 Apr APLD Applied Blockchain $2.15 / +0.04 (+1.90%) 07/22/22 Here's What You Missed in Crypto This Week 05/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/22 What You Missed On Wall Street On Monday 05/09/22 What You Missed On Wall Street This Morning 09/14/22 6th Annual Best Ideas Growth Conference: Big 6
Downgrade	K+S AG downgraded to Sector Perform from Outperform at Scotiabank » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 KPLUY K+S AG $10.87 / +0.28 (+2.64%) , NTR Nutrien $90.51 / +0.045 (+0.05%) , CF CF Industries $101.91 / +0.01 (+0.01%) Scotiabank analyst Ben… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/08/22 Nutrien name Ken Seitz as President and CEO 07/20/22 Nutrien to acquire Casa do Adubo, terms undisclosed 06/09/22 Nutrien announces plans to increase fertilizer production capacity 05/18/22 Denbury, Nutrien enter agreement for transportation and storage of CO2 CF CF Industries $101.91 / +0.01 (+0.01%) 07/18/22 CF Industries 'disappointed' by ITC injury determination on UAN imports 06/08/22 CF Industries to shut one of its U.K. manufacturing facilities 06/06/22 CF Industries exec Hoker sells 6,684 common shares 05/03/22 CF Industries, Mitsui announce plans for ammonia production facility in U.S. KPLUY NTR CF KPLUY K+S AG $10.87 / +0.28 (+2.64%) 07/18/22 Morgan Stanley K+S AG price target lowered to EUR 24 from EUR 26.50 at Morgan Stanley 05/12/22 Morgan Stanley K+S AG price target raised to EUR 26.50 from EUR 20.50 at Morgan Stanley 05/12/22 Scotiabank K+S AG price target raised to EUR 40 from EUR 38 at Scotiabank 04/20/22 DZ Bank K+S AG downgraded to Hold from Buy at DZ Bank NTR Nutrien $90.51 / +0.045 (+0.05%) 08/10/22 Barclays Nutrien price target lowered to $105 from $126 at Barclays 08/09/22 Scotiabank Nutrien upgraded to Outperform from Sector Perform at Scotiabank 07/18/22 RBC Capital ITC ruling against U.S. UAN tariffs negative for CF Industries, says RBC Capital 07/14/22 Credit Suisse Nutrien initiated with an Underperform at Credit Suisse CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Barclays CF Industries upgraded to Overweight from Equal Weight at Barclays 08/03/22 Scotiabank CF Industries upgraded to Outperform from Sector Perform at Scotiabank 08/03/22 Citi CF Industries upgraded to Buy on tighter ag conditions at Citi 08/03/22 Citi CF Industries upgraded to Buy from Neutral at Citi NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/03/22 Nutrien cuts FY22 EPS view to $15.80-$17.80 from $16.20-$18.70 08/03/22 Nutrien reports Q2 EPS $6.51, consensus $5.76 05/02/22 Nutrien raises FY22 EPS view to $16.20-$18.70 from $10.20-$11.80 05/02/22 Nutrien reports Q1 EPS $2.70, consensus $2.72 CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries reports Q2 EPS $5.58, consensus $6.12 08/01/22 Notable companies reporting after market close 05/04/22 CF Industries reports Q1 EPS $4.21, consensus $4.35 02/15/22 CF Industries reports Q4 EPS $3.27, consensus $3.51 CF CF CF Industries $101.91 / +0.01 (+0.01%) 03/22/22 Agriculture stocks see increased demand amid Ukraine turmoil, Bloomberg says NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 08/09/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/28/22 What You Missed On Wall Street This Morning 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/03/22 Fly Intel: Pre-market Movers CF CF Industries $101.91 / +0.01 (+0.01%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/03/22 What You Missed On Wall Street On Wednesday 08/03/22 What You Missed On Wall Street This Morning 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11/03/22 Nutrien - NTR NTR CF NTR Nutrien $90.51 / +0.045 (+0.05%) 06/23/22 Nutrien put volume heavy and directionally bearish 06/10/22 Nutrien put volume heavy and directionally bearish 06/03/22 Nutrien put volume heavy and directionally bearish 05/12/22 Nutrien call volume above normal and directionally bullish CF CF Industries $101.91 / +0.01 (+0.01%) 08/01/22 CF Industries options imply 5.1% move in share price post-earnings 07/18/22 CF Industries put volume heavy and directionally bearish 07/15/22 Unusually active option classes on open July 15th 07/14/22 CF Industries put volume heavy and directionally bearish
Hot Stocks	SciSparc issued Israeli patent for tech treating CNS disorders » 08:07 08/12/22 08/12 08:07 08/12/22 08:07 SPRC SciSparc $1.19 / -0.025 (-2.06%) SciSparc announced it has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News SPRC SciSparc $1.19 / -0.025 (-2.06%) 08/08/22 SciSparc announces Israeli Ministry of Health approval for ASD trial 08/01/22 SciSparc signs clinical trial agreement with Yale University 07/08/22 SciSparc to expand clinical operation to include U.S. site towards SCI-110 trial 07/07/22 SciSparc's JV MitoCareX Bio launches new laboratory facility in Israel
Recommendations	AppLovin price target lowered to $70 from $80 at DA Davidson » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 APP AppLovin $34.46 / -6.01 (-14.85%) , U Unity $54.30 / -1.21 (-2.18%) DA Davidson analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin drops 10% to $36.55 after reporting Q2 losses 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Unity wins three-year contract from CACI 08/09/22 ironSource drops 10% as AppLovin's Unity bid contingent on ironSource deal exit 08/09/22 AppLovin submits proposal to combine with Unity 08/09/22 AppLovin says proposal to combine would value Unity at $58.85 per share APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 BTIG AppLovin price target lowered to $53 from $60 at BTIG 08/11/22 Truist AppLovin price target lowered to $65 from $77 at Truist 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi U Unity $54.30 / -1.21 (-2.18%) 08/11/22 Credit Suisse ironSource downgraded to Neutral from Outperform at Credit Suisse 08/10/22 Citi AppLovin bid for Unity faces 'several challenges,' says Citi 08/10/22 Oppenheimer Unity price target raised to $60 from $54 at Oppenheimer 08/10/22 Benchmark Benchmark keeps Sell rating on Unity, doesn't think AppLovin acquires APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 AppLovin sees FY22 revenue $2.84B-$3.14B, consensus $3.29B 08/10/22 AppLovin reports Q2 EPS (6c), consensus 18c 08/10/22 Notable companies reporting after market close 08/09/22 AppLovin lowers FY22 revenue view to $2.84B-$3.14B from $3.14B-$3.44B U Unity $54.30 / -1.21 (-2.18%) 08/09/22 Unity sees FY22 revenue $1.3B-$1.35B, consensus $1.36B 08/09/22 Unity sees Q3 revenue $315M-$335M, consensus $346.87M 08/09/22 Unity reports Q2 EPS (18c), consensus (21c) 08/09/22 Notable companies reporting after market close 03 Dec APP U APP AppLovin $34.46 / -6.01 (-14.85%) 06/30/22 AppLovin cuts 12% of workforce, AdExchanger reports U Unity $54.30 / -1.21 (-2.18%) 08/02/22 Unity in talks to spin off China unit, Reuters reports 06/29/22 Unity lays off hundreds of workers, Kotaku reports APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/10/22 Fly Intel: After-Hours Movers 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter U Unity $54.30 / -1.21 (-2.18%) 08/10/22 #SocialStocks: Musk sells Tesla shares should he lose legal battle with Twitter 08/09/22 Fly Intel: After-Hours Movers 08/09/22 What You Missed On Wall Street On Tuesday 08/09/22 What You Missed On Wall Street This Morning APP U APP AppLovin $34.46 / -6.01 (-14.85%) 08/10/22 Applovin options imply 8.4% move in share price post-earnings 08/10/22 Largest borrow rate increases among liquid names 08/02/22 Largest borrow rate increases among liquid names 05/24/22 Applovin call volume above normal and directionally bullish U Unity $54.30 / -1.21 (-2.18%) 07/25/22 Unity Software put volume heavy and directionally bearish 07/12/22 Unity Software put volume heavy and directionally bearish 07/08/22 Unity Software call volume above normal and directionally bullish 06/16/22 Unity Software call volume above normal and directionally bullish
Hot Stocks	Terns Pharmaceuticals announces $65M oversubscribed offering » 08:06 08/12/22 08/12 08:06 08/12/22 08:06 TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) Terns Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 06/01/22 Terns Pharmaceuticals appoints Kerry Russell as chief medical officer 05/16/22 Terns Pharmaceuticals expects cash to fund operations into 2025 03/21/22 Terns Pharmaceuticals announces Part 1 of AVIATION trial met primary endpoint TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 JPMorgan Terns downgraded after 'firmly negative' data at JPMorgan 03/23/22 JPMorgan Terns Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan 09/14/21 Goldman Sachs Terns Pharmaceuticals assumed with a Buy at Goldman Sachs TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 05/16/22 Terns Pharmaceuticals reports Q1 EPS (55c), consensus (64c) 03/03/22 Terns Pharmaceuticals reports Q4 EPS (56c), consensus (63c) TERN Terns Pharmaceuticals $2.40 / +0.14 (+6.19%) 03/23/22 What You Missed On Wall Street On Wednesday 03/23/22 What You Missed On Wall Street This Morning 03/23/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Vontier appoints Anshooman Aga as CFO » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 VNT Vontier $24.16 / -0.315 (-1.29%) , HSC Harsco $6.56 / +0.04 (+0.61%) Vontier (VNT) announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/28/22 Vontier names Hani Joakim as Chief Technology Officer 07/19/22 Watts Water names Andre Dhawa Chief Operating Officer 02/22/22 Vontier announces $250M accelerated share repurchase agreement HSC Harsco $6.56 / +0.04 (+0.61%) 06:17 Today Harsco CFO Anshooman Aga stepping down, Pete Minan named Interim CFO 07/28/22 Clean Earth opens new 10-day hazardous waste transfer facility in Puerto Rico 07/15/22 Harsco falls -18.9% 07/15/22 Harsco falls -17.1% VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 07/08/22 Barclays Vontier price target lowered to $33 from $39 at Barclays 04/04/22 Barclays Vontier price target lowered to $40 from $42 at Barclays 03/23/22 Argus Vontier price target lowered to $30 from $40 at Argus 02/18/22 Citi Vontier price target lowered to $34 from $39 at Citi HSC Harsco $6.56 / +0.04 (+0.61%) 07/20/22 DA Davidson Harsco price target lowered to $13 from $16 at DA Davidson 07/18/22 Barrington Harsco price target lowered to $13 from $20 at Barrington 07/12/22 BMO Capital Harsco initiated with a Market Perform at BMO Capital 05/04/22 Barrington Harsco price target lowered to $20 from $22 at Barrington VNT HSC VNT Vontier $24.16 / -0.315 (-1.29%) 08/04/22 Vontier sees 2022 revenue $80M, consensus $3.19B 08/04/22 Vontier sees FY22 adjusted EPS $3.20-$3.30, consensus $3.24 08/04/22 Vontier sees Q3 adjusted EPS 85c-90c, consensus 91c 08/04/22 Vontier reports Q2 adjusted EPS 72c, consensus 70c HSC Harsco $6.56 / +0.04 (+0.61%) 08/02/22 Harsco lowers 2022 adjusted EPS view 0c-(13c) from 35c-45c, consensus 10c 08/02/22 Harsco sees Q3 adjusted EPS (2c)-(8c), consensus 6c 08/02/22 Harsco reports Q2 adjusted EPS 1c, consensus (1c) 07/15/22 Harsco sees FY22 GAAP operating loss of ($61M)-($51M) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6

Earnings	Checkpoint Therapeutics reports Q2 EPS (16c), consensus (17c) » 08:05 08/12/22 08/12 08:05 08/12/22 08:05 CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events Options CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 06/16/22 Checkpoint Therapeutics announces interim results from trial on cosibelimab 05/13/22 Checkpoint Therapeutics receives PIP waivers for cosibelimab from EMA CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 07/14/22 B. Riley Checkpoint Therapeutics resumed with a Buy at B. Riley 06/17/22 Lake Street Checkpoint cosibelimab data 'competitive,' says Lake Street 06/07/22 Lake Street Lake Street says Checkpoint warrants interest after cosibelimab 'shines' at ASCO 05/31/22 Cantor Fitzgerald Cantor sees 'positive' data likely coming from Checkpoint Therapeutics in June CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 05/12/22 Checkpoint Therapeutics reports Q1 EPS (20c), consensus (14c) 03/28/22 Checkpoint Therapeutics reports 2021 EPS (75c), consensus (51c) 09/14/22 6th Annual Best Ideas Growth Conference: Big 6 09/29/22 7th Annual Healthcare Conference CKPT Checkpoint Therapeutics $1.26 / +0.03 (+2.44%) 03/22/22 Checkpoint Therapeutics options imply 10.8% move in share price post-earnings 03/18/22 Checkpoint Therapeutics options imply 17.5% move in share price post-earnings 03/16/22 Checkpoint Therapeutics options imply 20.6% move in share price post-earnings
Hot Stocks	Longeveron expects cash to cover requirements into 1H24 » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 LGVN Longeveron $5.96 / -0.17 (-2.77%) Cash and short-term… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 08:03 Today Longeveron reports Q2 EPS (27c), consensus (23c) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN
Downgrade	ResMed downgraded to Neutral at Citi on valuation » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 RMD ResMed $241.21 / -2.37 (-0.97%) Citi analyst John… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed increases quarterly dividend 5% to 44c per share 08/02/22 ResMed acquires mementor, terms undisclosed 07/25/22 Philips sees completion of Respironics field action by first quarter of 2023 07/25/22 Berkeley Lights appoints Mehul Joshi as CFO RMD ResMed $241.21 / -2.37 (-0.97%) 06:33 Today RBC Capital ResMed downgraded to Sector Perform at RBC Capital on valuation 06:18 Today RBC Capital ResMed downgraded to Sector Perform from Outperform at RBC Capital 06:18 Today Citi ResMed downgraded to Neutral from Buy at Citi 06/06/22 RBC Capital ResMed upgraded to Outperform from Sector Perform at RBC Capital RMD ResMed $241.21 / -2.37 (-0.97%) 08/11/22 ResMed reports Q4 EPS $1.49, consensus $1.34 04/28/22 ResMed reports Q3 EPS $1.32, consensus $1.42 RMD ResMed $241.21 / -2.37 (-0.97%) 03/24/22 Early notable gainers among liquid option names on March 24th
Earnings	VYNE Therapeutics reports Q2 adjusted EPS (13c) vs (35c) last year » 08:04 08/12/22 08/12 08:04 08/12/22 08:04 VYNE VYNE Therapeutics / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings VYNE VYNE Therapeutics / + 08/10/22 VYNE announces Phase 2a trial of FMX144 did not meet primary endpoint 06/17/22 VYNE Therapeutics completes enrollment in Phase 2a trial of FMX114 05/10/22 VYNE Therapeutics hosting KOL even on InhiBET BET Inhibitor Platform 04/07/22 VYNE Therapeutics announces Phase 1b efficacy data for FMX114 VYNE VYNE Therapeutics / + 08/10/22 H.C. Wainwright VYNE Therapeutics price target lowered to $1.50 from $7 at H.C. Wainwright 01/13/22 Roth Capital Roth raises Journey Medical target to $17 after dermatology assets acquisition 12/06/21 H.C. Wainwright VYNE Therapeutics assumed with a Buy at H.C. Wainwright 08/13/21 Northland VYNE Therapeutics price target lowered to $6 from $12 at Northland VYNE VYNE Therapeutics / + 05/12/22 VYNE Therapeutics reports adjusted Q1 EPS (14c) vs (18c) last year 03/17/22 VYNE Therapeutics reports Q4 adjusted EPS (20c) vs (43c) last year
Earnings	Longeveron reports Q2 EPS (27c), consensus (23c) » 08:03 08/12/22 08/12 08:03 08/12/22 08:03 LGVN Longeveron $5.96 / -0.17 (-2.77%) Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron sees cash, equivalents funding operations into 1H24 05/09/22 Longeveron CEO Geoff Green to resign 04/13/22 Longeveron enters into CRADA with US Department of VA 04/05/22 Longeveron appoints Min as Chief Medical Officer LGVN Longeveron $5.96 / -0.17 (-2.77%) 03/24/22 Maxim Maxim starts Longeveron at Buy, sees stock as 'inexpensive later-stage play' 03/24/22 Maxim Longeveron initiated with a Buy at Maxim 01/05/22 EF Hutton Longeveron initiated with a Buy at EF Hutton LGVN Longeveron $5.96 / -0.17 (-2.77%) 05/13/22 Longeveron reports Q1 EPS (17c) vs. (18c) last year 03/11/22 Longeveron reports Q4 EPS (20c), two est. (25c) LGVN Longeveron $5.96 / -0.17 (-2.77%) 04/05/22 Fly Intel: After-Hours Movers 08:30 Today Longeveron - LGVN

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event
Today at 08:30

Import Prices Y/Y: July 2022 Government Event
Today at 08:30

Export Prices M/M: July 2022 Government Event
HOFV
Today at 08:30

Hall of Fame Resort & Entertainment - HOFV Conference Calls
KINS
Today at 08:30

Kingstone Companies - KINS Conference Calls
RGF
Today at 08:30

Real Good Food - RGF Conference Calls
AIRS
Today at 08:30

AirSculpt Technologies - AIRS Conference Calls
SHPW
Today at 08:30

Shapeways - SHPW Conference Calls
BR
Today at 08:30

Broadridge - BR Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

ACS downgraded to Neutral from Buy at Goldman Sachs

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access